▶HIV-protease inhibitorsare predicted to increase the exposure
toalpha blockers(doxazosin).oStudy
▶HIV-protease inhibitorsmoderately increase the exposure to
alprazolam. Avoid.oStudy
▶HIV-protease inhibitors(ritonavir, tipranavir)are predicted to
increase the exposure toamfetamines.rTheoretical
▶Ritonavirdecreases the exposure toaminophylline. Adjust
dose.oStudy
▶Ritonaviris predicted to decrease the exposure toanaesthetics,
local(ropivacaine).oTheoretical
▶Antacidsare predicted to decrease the absorption of
atazanavir.Atazanavirshould be taken 2 hours before or
1 hour afterantacids.rTheoretical
▶Antacidsare predicted to decrease the absorption of
tipranavir. Separate administration by 2 hours.oStudy
▶HIV-protease inhibitorsare predicted to increase the exposure
toantiarrhythmics(amiodarone). Avoid.rTheoretical→Also
seeTABLE 9p. 849
▶HIV-protease inhibitorsare predicted to increase the exposure
toantiarrhythmics(disopyramide).rTheoretical→Also see
TABLE 9p. 849
▶HIV-protease inhibitorsvery markedly increase the exposure to
antiarrhythmics(dronedarone). Avoid.rStudy→Also see
TABLE 9p. 849
▶HIV-protease inhibitorsare predicted to increase the exposure
toantiarrhythmics(lidocaine). Avoid.rStudy
▶HIV-protease inhibitorsare predicted to increase the exposure
toantiarrhythmics(propafenone). Monitor and adjust dose.
rStudy
▶HIV-protease inhibitorsare predicted to increase the exposure
toanticholinesterases, centrally acting(galantamine). Monitor
and adjust dose.oStudy
▶HIV-protease inhibitorsare predicted to increase the exposure
toantiepileptics(carbamazepine)andantiepileptics
(carbamazepine)are predicted to decrease the exposure to
HIV-protease inhibitors. Monitor and adjust dose.r
Theoretical
▶HIV-protease inhibitorsare predicted to affect the exposure to
antiepileptics(fosphenytoin, phenytoin)andantiepileptics
(fosphenytoin, phenytoin)decrease the concentration ofHIV-
protease inhibitors.rTheoretical
▶Ritonavirslightly decreases the exposure toantiepileptics
(lamotrigine).rStudy
▶HIV-protease inhibitorsare predicted to very slightly increase
the exposure toantiepileptics(perampanel).nStudy
▶HIV-protease inhibitorsare predicted to affect the
concentration ofantiepileptics(phenobarbital, primidone)and
antiepileptics(phenobarbital, primidone)are predicted to
decrease the concentration ofHIV-protease inhibitors.r
Theoretical
▶Ritonaviris predicted to decrease the concentration of
antiepileptics(valproate).rAnecdotal
▶Antifungals, azoles(fluconazole)slightly increase the exposure
totipranavir. Avoid or adjust dose.oStudy
▶Antifungals, azoles(miconazole)are predicted to increase the
concentration ofHIV-protease inhibitors. Use with caution and
adjust dose.oTheoretical
▶Antifungals, azoles(posaconazole)are predicted to increase the
exposure toHIV-protease inhibitors.oStudy
▶HIV-protease inhibitorsare predicted to increase the exposure
toantifungals, azoles(isavuconazole). Avoid or monitor side
effects.rStudy
▶HIV-protease inhibitorsare predicted to increase the exposure
toantifungals, azoles(itraconazole). Use with caution and
adjust dose.rStudy
▶HIV-protease inhibitorsare predicted to increase the exposure
toantifungals, azoles(ketoconazole). Use with caution and
adjust dose.oStudy
▶HIV-protease inhibitorsare predicted to affect the exposure to
antifungals, azoles(voriconazole)andantifungals, azoles
(voriconazole)potentially affect the exposure toHIV-protease
inhibitors.rStudy→Also seeTABLE 9p. 849
▶HIV-protease inhibitorsare predicted to increase the exposure
toantihistamines, non-sedating(mizolastine). Avoid.rStudy
▶HIV-protease inhibitorsare predicted to increase the exposure
toantihistamines, non-sedating(rupatadine). Avoid.o
Study
▶HIV-protease inhibitorsdecrease the exposure toantimalarials
(atovaquone). Avoid if boosted with ritonavir.oStudy
▶HIV-protease inhibitorsare predicted to increase the
concentration ofantimalarials(piperaquine).rTheoretical
▶HIV-protease inhibitorsare predicted to decrease the exposure
toantimalarials(proguanil). Avoid.oStudy
▶HIV-protease inhibitorsare predicted to affect the exposure to
antimalarials(quinine).rStudy→Also seeTABLE 9p. 849
▶Ritonaviris predicted to increase the exposure toapixaban.
Avoid.rTheoretical
▶HIV-protease inhibitorsare predicted to markedly increase the
exposure toaprepitant.oStudy
▶HIV-protease inhibitorsare predicted to slightly increase the
exposure toaripiprazole. Adjustaripiprazoledose,p. 249.
oStudy
▶HIV-protease inhibitorsare predicted to increase the exposure
toaxitinib. Avoid or adjust dose.oStudy
▶HIV-protease inhibitorsare predicted to increase the exposure
tobedaquiline. Avoid prolonged use.nStudy→Also see
TABLE 9p. 849
▶HIV-protease inhibitors(lopinavir, ritonavir, saquinavir)are
predicted to increase the exposure tobeta blockers, non-
selective(nadolol).oStudy
▶Ritonaviris predicted to increase the exposure tobeta blockers,
selective(metoprolol).oStudy
▶HIV-protease inhibitorsare predicted to increase the exposure
tobeta 2 agonists(salmeterol). Avoid.rStudy
▶HIV-protease inhibitorsslightly increase the exposure to
bortezomib.oStudy
▶HIV-protease inhibitorsare predicted to increase the exposure
tobosentan.rStudy
▶HIV-protease inhibitorsare predicted to markedly increase the
exposure tobosutinib. Avoid or adjust dose.rStudy→
Also seeTABLE 9p. 849
▶Ritonaviris predicted to decrease the exposure tobupropion.
oStudy
▶HIV-protease inhibitorsare predicted to increase the exposure
tobuspirone. Adjustbuspironedose.rStudy
▶HIV-protease inhibitorsslightly increase the exposure to
cabozantinib.oStudy→Also seeTABLE 9p. 849
▶Ritonaviris predicted to moderately increase the clearance of
caffeine citrate. Monitor and adjust dose.oStudy
▶HIV-protease inhibitorsare predicted to increase the exposure
tocalcium channel blockers(amlodipine, felodipine, lacidipine,
nicardipine, nifedipine, nimodipine). Monitor and adjust dose.
oStudy
▶HIV-protease inhibitorsare predicted to increase the exposure
tocalcium channel blockers(diltiazem, verapamil).rStudy
▶HIV-protease inhibitorsare predicted to markedly increase the
exposure tocalcium channel blockers(lercanidipine). Avoid.
rStudy
▶HIV-protease inhibitorsare predicted to increase the exposure
tocannabis extract. Use with caution and adjust dose.
oTheoretical
▶HIV-protease inhibitorsare predicted to increase the exposure
toceritinib. Avoid or adjustceritinibdose.rStudy→Also
seeTABLE 9p. 849
▶HIV-protease inhibitorsincrease the concentration of
ciclosporin.rStudy
▶HIV-protease inhibitorsare predicted to moderately increase
the exposure tocilostazol. Adjustcilostazoldose.o
Study
▶HIV-protease inhibitorsare predicted to moderately increase
the exposure tocinacalcet. Adjust dose.oStudy
▶Ritonaviris predicted to affect the exposure toclozapine.
Avoid.rTheoretical
▶HIV-protease inhibitorsare predicted to markedly increase the
exposure tocobimetinib. Avoid or monitor for toxicity.r
Study
▶HIV-protease inhibitorsare predicted to increase the exposure
tocolchicine. Avoid potent inhibitors of CYP3A4 or adjust
colchicinedose.rStudyBNFC 2018 – 2019 HIV-protease inhibitors—HIV-protease inhibitors 929
Interactions|Appendix 1A1